scholarly journals Serum Cystatin-C levels could be predictor of Diastolic Heart Failure

2018 ◽  
pp. 194-197
Author(s):  
Osman Kayapinar ◽  
cem özde ◽  
adnan kaya
Keyword(s):  
Heart Failure ◽  
Cystatin C ◽  
Diastolic Heart Failure ◽  
Serum Cystatin C ◽  
Serum Cystatin

scholarly journals Predictive Value of the Serum Cystatin C/Prealbumin Ratio in Combination With NT-proBNP Levels for Long-Term Prognosis in Chronic Heart Failure Patients: A Retrospective Cohort Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Chuanhe Wang ◽  
Su Han ◽  
Fei Tong ◽  
Ying Li ◽  
Zhichao Li ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cystatin C ◽  
Cardiovascular Mortality ◽  
Retrospective Cohort ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
All Cause Mortality ◽  
Long Term Prognosis

Aim: The present study was established to investigate the use of the serum cystatin C/prealbumin (Cys-C/PAB) ratio as a predictive factor for long-term prognosis in patients with chronic heart failure.Methods: We divided our retrospective cohort of 6,311 patients admitted to hospital due to an episode of heart failure (HF) into three groups according to the Cys-C/PAB ratio. The endpoints were cardiovascular and all-cause mortality. Median follow-up time were 3.3 years (2–8 years), during which 2,945 (46.7%) patients died.Results: The Cys-C/PAB ratio was revealed to be an independent predictor of cardiovascular mortality (HR: 1.12, 95% CI: 1.15–1.23, P < 0.01) and all-cause mortality (HR: 1.19, 95% CI: 1.13–1.24, P < 0.01) by multivariable Cox analysis. Integrated discrimination improvement (IDI) showed that the Cys-C/PAB ratio in conjunction with the level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) conferred a significant improvement in predicting individual risks of cardiovascular (P = 0.023) and all-cause (P = 0.028) mortality. For those with a high Cys-C/PAB ratio in combination with a high NT-proBNP level, the long-term cardiovascular mortality risk ratio was 8.6-times higher than for those with low values, and 7.51-times for all-cause mortality. Our study also showed that Cys-C/PAB and NT-proBNP in combination displayed higher value for the prediction of cardiovascular and all-cause in-hospital mortality in patients with HF.Conclusions: The Cys-C/PAB ratio is valuable for predicting cardiovascular and all-cause mortality in patients with HF and offers additional information to that provided by NT-proBNP.

scholarly journals Prognostic Value of Serum Cystatin C in Patients after Acute Heart Failure

2012 ◽  
Vol 25 (5) ◽  
pp. 625-625
Author(s):  
Wei-fu OU-YANG ◽  
Wen-qiang JIANG ◽  
Mei-qun HUANG ◽  
Lian-zhen YE ◽  
Min-jing CHEN
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Cystatin C ◽  
Prognostic Value ◽  
Serum Cystatin C ◽  
Serum Cystatin

Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure

2012 ◽  
Vol 23 (7) ◽  
pp. 599-603 ◽  
Author(s):  
Juan Ignacio Pérez-Calvo ◽  
Francisco José Ruiz-Ruiz ◽  
Francisco Javier Carrasco-Sánchez ◽  
José Luis Morales-Rull ◽  
Sergio Manzano-Fernández ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Natriuretic Peptide ◽  
Cystatin C ◽  
Prognostic Value ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
C And N

Sacubitril-Valsartan Improves Anemia Of Cardiorenal Syndrome

2020 ◽  
Vol 18 ◽  
Author(s):  
Nicolás Roberto Robles ◽  
Rosa Diaz Campillejo ◽  
Julian Valladares ◽  
Elena Garcia de Vinuesa ◽  
Juan Villa ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cystatin C ◽  
Cardiorenal Syndrome ◽  
Short Term ◽  
Serum Cystatin C ◽  
Novel Therapy ◽  
Serum Cystatin ◽  
Reduced Ejection Fraction ◽  
Prevalence Of Anemia

Background and Aims: Anemia is a common complication of heart failure and chronic kidney disease (CKD). Sacubitril-valsartan is a novel therapy for the treatment of chronic heart failure with a reduced ejection fraction (HFrEF). We have evaluated the short-term effects of sacubitril-valsartan on the anemia of CRS. Methods: The study group comprised 39 patients with HFrEF, who were followed-up for three months. The study is a retrospective analysis of clinical data. Data of 3 months’ visit and baseline visit were recorded including: plasmatic creatinine, glomerular filtration rate, cystatin C, kaliemia, haemoglobin, pro-BNP and albuminuria. Results: In all, 34 patients ended the follow-up. Mean sacubitril-valsartan dosage at baseline was 101±62 mg/day and 126±59 mg/day at end. Mean hemoglobin increased from 12.2±1.1 g/dl at baseline to 12.9±1.0 g/dl (p = 0.001,). Prevalence of anemia was 64.7% (95%CI,47.9-78.5%) at baseline and 38.4 (95%CI,23.9-55.0%) after the follow-up (p = 0.016). Serum cystatin C levels decreased from 2.71±1.0 to 2.48±1.0 mg/l (p = 0.028). Serum K levels remained unchanged (baseline 4.94±0.60, three months visit 4.94±0.61 mmol/l, p = 0.998). Conclusions: Sacubitril-valsartan improves anemia in CRS patients. An improvement of serum cystatin levels was observed. Few untoward effects were detected. These findings should be confirmed in wider clinical trials.

Sign in / Sign up

Export Citation Format

Share Document